Fig. 3From: Tocilizumab improves 28-day survival in hospitalized patients with severe COVID-19: an open label, prospective studyForest plot of the primary endpoint (mortality) in prespecified subgroups. Estimates are based on a Cox proportional-hazards modelBack to article page